We regularly have new studies that we are recruiting for. If you don’t see something that you qualify for right now, please call Caitlin at 952-993-9605 to be contacted about future studies.
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec (COMBINE 1)
Principal Investigator: Richard Bergenstal, MD
Study sponsor: Novo Nordisk
Location: International Diabetes Center
Phase of Study: III
Purpose of study: We are doing this study to see how the new medicine IcoSema controls blood sugar levels in people with type 2 diabetes. IcoSema is a medication taken once a week and is a combination of insulin icodec and another medication called semaglutide. The study will also look at how well IcoSema reduces body weight and reduces the risk of low blood sugar level (hypoglycemia). Study participants will receive either IcoSema or insulin icodec and this will be used in place of participants’ usual long-acting insulin during the study.
Participants will be provided with:
• Compensation for completed study visits
• Study medication
• Blood glucose meter and supplies
• Study-related medical care and lab tests
• Diabetes management and education, support and guidance provided by diabetes professionals
Inclusion Criteria:
The study is accepting individuals ages 18 and older who:
– Have type 2 diabetes
– Use long-acting insulin, 1-2 injections a day
– Meet other study specific criteria
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
A Study of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Principal Investigator: Richard Bergenstal, MD
Study sponsor: Eli Lilly and Company
Location: International Diabetes Center
Phase of Study: Phase III
Purpose of study: We are testing a new investigational insulin (LY3209590) that is designed to be taken only once a week. The study will be looking at how well LY3209590 works for managing participant blood sugars, and to evaluate how it works compared to insulin degludec (a once-daily long acting insulin which is currently available for use). Insulin will be provided to participants during the study.
Inclusion Criteria:
The study is accepting individuals 18 and older who:
– Have type 2 diabetes
– Use long acting insulin, 1-2 injections a day
– Meet other study specific criteria
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Comparing Fingerstick Blood Glucose Monitoring versus Continuous Glucose Monitoring in Primary Care (The “GluCoCare” Study: GLUcose monitoring COmparison in primary CARE)
Principal Investigator: Richard Bergenstal, MD, Thomas Martens, MD
Study sponsor: Patient-Centered Outcomes Research Institute
Location: 10 select Primary Care Clinics across the HealthPartners network
Purpose of study: Your primary care clinic providers are partnering with the International Diabetes Center to invite you to join the GluCoCare study, a study looking at how using fingerstick blood glucose monitoring (BGM) compares to using continuous glucose monitoring (CGM) to manage type 2 diabetes in people using insulin.
In case you’re not familiar with a CGM, it is a device used to measure your glucose level every few minutes, 24 hours a day. CGM lets you see your current glucose level and shows you if your glucose is going up, down or staying steady. You can also see daily glucose patterns over time.
While it is known that controlling blood glucose is important in managing diabetes, especially when using insulin, it is not yet known which of the two ways to measure blood glucose is better. This important study will help people with type 2 diabetes know which method of measuring glucose is more helpful in improving glucose levels and decreasing the work of managing diabetes. We’re hoping you’ll partner with us to learn if using BGM or CGM is better to help manage blood glucose.
Inclusion Criteria:
This study is accepting individuals ages 18-75 who:
– Have type 2 diabetes
– Have a hemoglobin A1c 7.5-12
– Currently use insulin
– Are not currently using continuous glucose monitoring
– Currently receiving care at one of 30 clinics within the HealthPartners system
– Meet other study specific requirements
Participants will receive compensation for completed study visits up to a total of $250 if all visits are completed.
If you are interested in participating and would like to see if you are eligible, please click here to answer some eligibility questions.
Study Contact:
GluCoCare Team
(952) 967-5805
Control-IQ Technology for High Insulin Users with Type 1 Diabetes (Higher IQ)
Principal Investigator: Anders Carlson, MD
Study sponsor: Tandem Diabetes Care, Inc.
Location: International Diabetes Center
Purpose of study: This study will test the T:slim X2 insulin pump with Control-IQ 1.5 technology. The system is investigational and includes changes from the currently FDA approved Control IQ technology. This system consists of an insulin pump, a glucose sensor, and a transmitter. It uses continuous glucose sensor information to tell the pump how to adjust insulin to help control glucose levels in people who have type 1 diabetes. This study will test how the insulin pump works for participants with type 1 diabetes who intend to use at least 1 basal insulin rate above 3 units per hour. Participation in the study will last about 15 weeks.
Participants will be provided with:
• Study approved insulin at no cost
• Pump, glucose monitoring device and supplies used during the study, provided at no cost
• Diabetes management and education, support and guidance by diabetes professionals
• Compensation for completed study visits
Inclusion Criteria:
The study is accepting individuals 18 years old and older who:
• Have type 1 diabetes and have been using an insulin pump for at least the past 3 months AND
– Intend on using at least 1 basal rate above 3 units/hour on U-100 insulin OR
– Individuals currently using U-200 with their pump may also qualify OR
– Current pump users who also take a separate long-acting insulin injection may also qualify
• Have a hemoglobin A1c less than 10.5%
• Are willing and able to upload glucose and pump data between visits
• Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Evaluation of Flash Continuous Glucose Monitoring to Reduce Hyperglycemia in People with T2 Diabetes (FLASH)
Principal Investigator: Thomas Martens, MD
Study Sponsor: Abbott Diabetes Care
Location: International Diabetes Center
Purpose of study: The goal of this study is to decrease the amount of time that a person with type 2 diabetes spends with blood glucose in high ranges through the use of a continuous glucose monitoring (CGM) system. The study will help participants focus on changing their food choices and other behaviors that can have an effect on glucose. All participants in the study will be provided with the FreeStyle Libre CGM system. This CGM system is FDA approved and currently available for use. It has a sensor that measures a person’s glucose level continuously. Participants in this study will either use the FreeStyle Libre CGM system alone, or in combination with a new smartphone app that is used to log and understand the effect of foods on glucose.
Inclusion Criteria: The study is accepting males and females ages 18 and older who:
-Have type 2 diabetes
-Are taking at least 1 medication (non-insulin) to treat their diabetes
-Have an AIC between 7.5-12.0%
-Meet other study specific requirements
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
IMPACT2: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2 – Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes
Principal Investigator: Richard Bergenstal, MD
Study sponsor: Medtronic
Location: International Diabetes Center
Purpose of study: The purpose of this study is to see how well the Minimed 780G insulin pump system works to automatically infuse insulin for control of glucose levels for people with type 2 diabetes who use insulin. This Medtronic MiniMed 780G system consists of an insulin pump, a glucose sensor, a transmitter, and a glucose meter. The system uses continuous glucose readings from the sensor information to tell the insulin pump how much insulin to infuse automatically to help control glucose levels in people who have type 2 diabetes. The MiniMed 780 System and related supplies are provided for use during the study at no cost to qualifying participants.
Involvement in the trial will include:
• Compensation for completed study visits
• Diabetes management and education, support and guidance by diabetes professionals
• Study-related medical care, including regular health checks and lab tests provided at no cost to you
Inclusion Criteria:
The study is accepting individuals ages 18-80 who:
– Have had type 2 diabetes for 2 years or longer
– Take insulin injections or use an insulin pump
– Are willing to use Humalog or Novolog insulin throughout the study
– Meet other study specific criteria
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Multi-center, Randomized, Parallel, Adaptive, Controlled Trial in Adult and Pediatric Patients with Type 1 Diabetes Using Hybrid Closed Loop System and Control (CSII, MDI and SAP) at Home (Medtronic 304)
Principle Investigator: Anders Carlson, MD
Study Sponsor: Medtronic Minimed
Location: International Diabetes Center
Purpose of Study: The purpose of this study is to look at the safety and effectiveness of the hybrid closed loop (HCL) insulin pump system, MiniMed 770G, used in a home setting by people with type 1 diabetes. This system consists of an insulin pump, a Medtronic glucose sensor, an insertion device for the sensor, a transmitter and a glucose meter. The HCL uses continuous glucose sensor information to tell the insulin pump how much insulin to infuse automatically to help control glucose levels in people who have type 1 diabetes. The MiniMed 770G has been approved by the FDA for use in the United States for ages 2 and older. Study participants will be randomly assigned so that about half will use the insulin pump in the HCL mode. The other half will either continue with multiple daily injections, if that is what they are currently using, or use the MiniMed 770G either with CGM (but without HCL mode) depending on their pre-study therapy. After about 6 months, all participants will use the insulin pump in the HCL mode using the continuous glucose monitor sensor.
Inclusion Criteria:
– 65-80 years old
– Have had type 1 diabetes for 3 months or longer
– Take insulin injections or use an insulin pump
– Are willing to use Humalog or Novolog insulin throughout the study
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@ParkNicollet.com
Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev™ (insulin Lispro-aabc) (CIP-335)
Principal Investigator: Richard Bergenstal, MD
Study sponsor: Medtronic
Location: International Diabetes Center
Purpose of study: A recent advance in diabetes technology includes automated insulin delivery (closed loop) systems that automatically adjust the amount of insulin given to keep glucose levels near a target value. The MiniMed 780G system, using the Guardian 4 Sensor, is an investigational automated insulin delivery system that does not require calibration. This study is being done to learn about the use of Lyumjev insulin with the 780G system. Lyumjev is an ultra-fast acting insulin with many of the same active ingredients as Humalog. It is approved for use in adults but is being used in an investigational way in this study.
Participants will be provided with:
• Lyumjev insulin
• The Minimed 780G insulin pump system with the Guardian 4 CGM, including related supplies, as well as glucose
meter and strips, is provided for use during the study at no cost to you.
• Compensation for completed study visits
• Study-related medical care and lab tests, provided at no cost
• Diabetes management and education, support and guidance provided by diabetes professionals
Inclusion Criteria:
The study is accepting individuals ages 18-80 who:
– Have had type 1 diabetes for at least 2 years
– Have been using an insulin pump for at least the past 6 months
– Are willing to use the study insulin pump system with Lyumjev insulin
– Meet other study specific criteria
Study Contact:
Caitlin Moening
(952) 993-9605
IDCResearch@parknicollet.com
Weight Loss Wizard: Patient Perspective Interviews (Weight Loss Wizard)
Principal Investigator: Patrick O’Connor, MD, MPH, MA
Study sponsor: NIH/NIDDK
Location: Enrolled participants do not need to travel
Purpose of study: The Weight Loss Wizard participant interview is supported by National Institutes of Health to gather input from patients about their experiences with talking to their primary care doctors about weight loss options. The information gathered will help guide design and content of a shared decision-making tool used at the point of care. The interview is being offered via phone or conference call to patients with Type 2 Diabetes.
Inclusion Criteria:
-Patients with Type 2 Diabetes
Exclusion Criteria:
-Previous metabolic bariatric surgery
Study Contact:
Center for Evaluation and Survey Research
(952) 967-6912
WeightLossWizard@HealthPartners.com
